<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04032509</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.176</org_study_id>
    <secondary_id>2019-A01525-52</secondary_id>
    <nct_id>NCT04032509</nct_id>
  </id_info>
  <brief_title>A Study of Biomarkers of Mild Traumatic BRAIN Injury</brief_title>
  <acronym>BRAINI</acronym>
  <official_title>A Prospective Clinical Study of Biomarkers of Mild Traumatic BRAIN Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with mild traumatic brain injury (mTBI) represent a burden of patients admitted to&#xD;
      the emergency department. According to the guidelines, a cerebral CT scan is indicated after&#xD;
      mTBI according to the specific conditions. However, variability exists regarding the respect&#xD;
      of these CT scan indications, and less than 10% of patients will have visible brain lesions&#xD;
      on CT scan. Recently, serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal&#xD;
      Hydrolase-L1 (UCH-L1) biomarkers have shown ability to differentiate normal and abnormal CT&#xD;
      scan findings after mTBI. These encouraging results prompted us to launch a prospective study&#xD;
      using automated and quick measurements of GFAP and UCH-L1 biomarkers to validate these&#xD;
      findings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2019</start_date>
  <completion_date type="Actual">September 28, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of the VIDAS-BTI assay in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and their corresponding lower limit of 95% confidence interval by comparison with brain CT scan findings.</measure>
    <time_frame>12 hours post Traumatic Brain Injury (TBI)</time_frame>
    <description>2 x 5mL blood sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the added value of the two biomarkers measurements to Transcranial Doppler (TCD) performed on admission to detect patients at risk of neurological worsening and patients allowed for a safe return home</measure>
    <time_frame>Admission</time_frame>
    <description>TCD measures at admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the added value of the two biomarkers measurements to Transcranial Doppler (TCD) performed on admission to detect patients at risk of neurological worsening and patients allowed for a safe return home</measure>
    <time_frame>7 days after traumatic brain injury (TBI)</time_frame>
    <description>Neurological status at 1 week after TBI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the added value of the two biomarkers measurements to Transcranial Doppler (TCD) performed on admission to detect patients at risk of neurological worsening and patients allowed for a safe return home</measure>
    <time_frame>7 days after traumatic brain injury (TBI)</time_frame>
    <description>Quality of life after brain injury (QOLIBRI) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination the potential of the two biomarkers in predicting neurological outcome</measure>
    <time_frame>3 month after TBI</time_frame>
    <description>Extended Glasgow Outcome Scale (GOSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the potential of the two biomarkers in predicting neurological outcome</measure>
    <time_frame>3 month after TBI</time_frame>
    <description>Quality of life after brain injury (QOLIBRI) Questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the potential of the two biomarkers in predicting neurological outcome</measure>
    <time_frame>3 month after TBI</time_frame>
    <description>EuroQuol 5 dimensions 5 level questionnaire (EQ-5D-5L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the potential of the two biomarkers in predicting neurological outcome</measure>
    <time_frame>3 month after TBI</time_frame>
    <description>Rivermead Post-concussion symptoms Questionnaire (RPQ)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1501</enrollment>
  <condition>Mild Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Mild TBI</arm_group_label>
    <description>Mild TBI (GCS 13-15 on admission) within 12 hours after injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 x 5 mL blood sample</intervention_name>
    <description>2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.</description>
    <arm_group_label>Mild TBI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1600 patients: 1300 patients in France and 300 patients in Spain&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;18 years old (France)&#xD;
&#xD;
          -  Mild TBI (GCS 13-15 on admission) within 12 hours after injury&#xD;
&#xD;
          -  Indication of brain CT scan:&#xD;
&#xD;
               -  neurological focal deficit&#xD;
&#xD;
               -  anterograde amnesia&#xD;
&#xD;
               -  Glasgow coma scale score &lt;15 after 2 hours post-TBI&#xD;
&#xD;
               -  suspicion of vault depression fracture&#xD;
&#xD;
               -  fracture of the basal skull&#xD;
&#xD;
               -  persisting nausea, vomiting or headache&#xD;
&#xD;
               -  post-TBI seizures&#xD;
&#xD;
               -  Pre-injury treatment with antithrombotic drugs&#xD;
&#xD;
               -  Loss of consciousness or amnesia with age &gt;65 years, fall &gt;1m or hit pedestrian&#xD;
&#xD;
               -  Other condition requiring CT scan according to the in-charge physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  GCS 3-12 on admission&#xD;
&#xD;
          -  Time of injury unknown&#xD;
&#xD;
          -  Time to injury exceeding 12 hours&#xD;
&#xD;
          -  Primary admission for non-traumatic neurological disorder (e.g., stroke, spontaneous&#xD;
             intracranial hematoma)&#xD;
&#xD;
          -  Penetrating head trauma&#xD;
&#xD;
          -  Patient with mechanical ventilation&#xD;
&#xD;
          -  Pre-injury neurological disorder affecting the assessment of neurological outcome:&#xD;
             dementia, Parkinson's disease, multiple sclerosis, seizure disorder, brain tumor, and&#xD;
             history of neurosurgery, stroke or transient ischemic attack (TIA) within the last 30&#xD;
             days&#xD;
&#xD;
          -  Venipuncture not feasible&#xD;
&#xD;
          -  No realization of brain CT-scan&#xD;
&#xD;
          -  Subject under judiciary control&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Subject in exclusion period of another study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard HERRIOT - HCL</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lyon Sud HCL</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Ouest de Villefranche sur Saône</name>
      <address>
        <city>Villefranche-sur-Saône</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Tajo</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

